Publications

Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer

Gibson V, Dzialo J, Messier T, Bzura A, Poile C, Rogel J, Hahne JC, Habibovic A, Stead S, Saaman A, Blyth KG, Szlosarek PW, Lord S, Thistlethwaite F, Zhang M, Nakas A, Wells-Jordan P, Kutywayo K, Butnor KJ, Heintz NH, Naumov GN, Dungey M, Herrero Colomina J, Aktas B, Dulloo S, Spicer J, Fennell DA & Cunniff B.

DOI: 10.1038/s41467-026-75153-y · NCT05278975